Market Overview

Innovus Pharma to Present at H.C. Wainwright 20th Annual Global Investment Conference


Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the "Company") (OTCQB
Venture Market: INNV), an emerging commercial-stage pharmaceutical
company that delivers safe, innovative and effective over-the-counter
medicine and consumer care products to improve men's and women's health
and respiratory diseases, today announced that Dr. Bassam Damaj,
President & Chief Executive Officer, and Ryan Selhorn, Vice President,
Chief Financial Officer, will present at the 2018 H.C. Wainwright 20th
Annual Global Investment Conference, on Thursday, September 6, 2018.
They will present an update on the Company's growing revenues, the
launch of new products, its path to profitability and its other business

Dr. Damaj and Mr. Selhorn will be meeting with members of the investment
community during one-on-one meetings at the conference as well. The
corporate presentation will be available for download on the Innovus
Pharma web site (

About Conference Presentation Time

Event: H.C. Wainwright 20th Annual Global Investment

Date: Thursday, September 6, 2018

Time: 10:25 AM-10:50 AM EDT

Location: St. Regis New York at 2 E 55th St., New York, NY

About Innovus Pharmaceuticals, Inc.

Headquartered in San Diego, Innovus Pharma is an emerging OTC consumer
goods and specialty pharmaceutical company engaged in the
commercialization, licensing and development of safe and effective
non-prescription medicine and consumer care products to improve men's
and women's health and vitality and respiratory diseases. Innovus Pharma
delivers innovative and uniquely presented and packaged health solutions
through its (a) OTC medicines and consumer and health products, which we
market directly; (b) commercial partners to primary care physicians,
urologists, gynecologists and therapists; and (c) directly to consumers
through our on-line channels, retailers and wholesalers. The Company is
dedicated to being a leader in developing and marketing new OTC and
branded Abbreviated New Drug Application ("ANDA") products. The Company
is actively pursuing opportunities where existing prescription drugs
have recently, or are expected to, change from prescription (or Rx) to

For more information, go to;;;;;;;;;;;;;;;;

Innovus Pharma's Forward-Looking Safe Harbor:

Statements under the Private Securities Litigation Reform Act, as
amended: with the exception of the historical information contained in
this release, the matters described herein contain forward-looking
statements that involve risks and uncertainties that may individually or
mutually impact the matters herein described for a variety of reasons
that are outside the control of the Company, including, but not limited
to, projected revenues its products, estimated market for its products,
and statements about achieving its other development, growth,
commercialization, financial and staffing objectives. Readers are
cautioned not to place undue reliance on these forward-looking
statements as actual results could differ materially from the
forward-looking statements contained herein. Readers are urged to read
the risk factors set forth in the Company's most recent filing on Form
S-1, annual report on Form 10-K, subsequent quarterly reports filed on
Form 10-Q and other filings made with the SEC. Copies of these reports
are available from the SEC's website or without charge from the Company.

View Comments and Join the Discussion!